The News: The US Food and Drug Administration on Monday (October 2, 2017) announced a series of measures designed to speed to market generic versions of complex drugs such as… Read more »
The News: Teva Pharmaceutical Industries Ltd., which has been without a permanent CEO for six months, plunged $11.74, or 36% last week, to $20.60–the most in almost two decades. The… Read more »
The News: Teva Pharmaceutical Industries Ltd. (Petach Tikva ISR) suddenly found itself without a permanent CEO on Tuesday (February 7, 2017) after Erez Vigodman stepped down, leaving new management to… Read more »
The News: A US court invalidated four patents covering Teva Pharmaceutical Industries Ltd.’s (Petach Tikva ISR) three-times weekly version of Copaxone (glatiramer acetate) based on obviousness, following a challenge by… Read more »
Biogen Inc. (Cambridge MA) said Monday (December 19, 2016) it has named veteran biopharmaceutical executive Michel Vounatsos, head of the company’s commercial organization, its next chief executive. Mr. Vounatsos will succeed George Scangos, who announced earlier this… Read more »
Teva Pharmaceutical Industries Ltd. (Petach Tikva ISR) had a third patent on its top-selling multiple sclerosis drug, Copaxone, invalidated last Thursday by a U.S. agency, a further blow to its… Read more »
